IChondroitin Sulfate

Umxholo

• Inokwenzeka ukuba isebenze ...
• Akukho bungqina baneleyo bokulinganisa ukusebenza ...
• Amanyathelo okhuseleko kunye nezilumkiso:

IChondroitin sulphate yimichiza efumaneka rhoqo kwi-cartilage ejikeleze amalungu emzimbeni. I-Chondroitin sulphate ihlala yenziwe kwimithombo yezilwanyana, enje nge-shark kunye ne-cartilage yeenkomo. Inokwenziwa kwilebhu.

Ezinye iimveliso ze-chondroitin sulfate azibhalwanga ngokuchanekileyo. Kwezinye iimeko, inani le-chondroitin liye lahluka ukusuka kwelinye ukuya ngaphezu kwe-100% yemali echazwe kwileyibhile yemveliso. Kwakhona, ezinye iimveliso zinechondroitin ethathwe kwizilwanyana ezahlukeneyo, nangona oku kungasoloko kuchazwa kwileyibhile.

I-chondroitin sulfate isetyenziselwa i-osteoarthritis kunye ne-cataract. Ihlala isetyenziswa ngokudibanisa nezinye izinto, kubandakanya i-manganese ascorbate, i-hyaluronic acid, i-collagen peptides, okanye i-glucosamine. I-Chondroitin sulphate nayo iyathathwa ngomlomo, ifakwe eluswini, kwaye inikezwe njengendawo yokudubula kwezinye iimeko ezininzi, kodwa abukho ubungqina obuchanekileyo benzululwazi obuxhasa ezi zinto zisetyenziswayo.

Amayeza endalo aVimba weDatha Ukusebenza kwexabiso ngokusekwe kubungqina besayensi ngokwala manqanaba alandelayo: Ukusebenza, ukusebenza ngokukuko, okunokwenzeka ukuba kusebenze, okungenzeka kungasebenzi, kunokwenzeka ukungasebenzi, ukungasebenzi, kunye nobungqina obungonelanga bokulinganisa.

Ukulinganiswa kokusebenza kwe I-CHONDROITIN SULFATE zezi zilandelayo:

Inokwenzeka ukuba isebenze ...

• Iimpawu. Uphando lubonisa ukuba inaliti yesisombululo equkethe i-chondroitin sulphate kunye ne-sodium hyaluronate elisweni ikhusela iliso ngexesha lotyando lwamehlo. Iimveliso ezininzi ezahlukeneyo eziqukethe i-chondroitin sulfate kunye ne-sodium hyaluronate ziye zajongwa kwakhona yi-US Food and Drug Administration (FDA) ukuze zisetyenziswe ngexesha lotyando lwamehlo. Nangona kunjalo, akucaci ukuba ukongeza i-chondroitin sulphate kwizisombululo ze-hyaluronate zesodium kunceda ukunciphisa uxinzelelo ngaphakathi kwamehlo emva kotyando lwe-cataract xa kuthelekiswa nolunye unyango olufanayo. Olunye uphando lwakwangoko lubonisa ukuba isisombululo esithile esine-chondroitin sulphate kunye ne-hyaluronate (i-Viscoat, i-Alcon Laboratories) sinokunciphisa uxinzelelo kwiso kwaye siphucule impilo yeliso lilonke emva kokuba ikaract isuswe. Nangona kunjalo, amathontsi akabonakali ebhetele kunamathontsi aqukethe i-hyaluronate yodwa okanye enye imichiza ebizwa ngokuba yi-hydroxypropylmethyl-cellulose. Iziphumo zezisombululo eziqukethe kuphela i-chondroitin sulfate kutyando lwekati azaziwa.
• Osteoarthritis. Uphando lwezonyango lubonisa ukuba ukuthatha i-chondroitin sulphate ngomlomo kuthoba iintlungu kunye nokusebenza kwabanye abantu abane-osteoarthritis xa isetyenziselwa ukuya kuthi ga kwiinyanga ezi-6. Kubonakala ngathi kusebenza kakuhle kubantu abaneentlungu ezinzima kwaye xa kusetyenziswa ulungiselelo lwebanga lokuxuba amayeza. Iimveliso ezithile ezibonise izibonelelo kwizigulana ezine-osteoarthritis zibandakanya iChondrosulf (IBSA Institut Biochimique SA), Chondrosan (Bioibérica, SA), kunye neStructrum (Laboratoires Pierre Fabre). Kodwa ukukhululeka kwentlungu kusenokwenzeka ukuba kuncinci. Olunye uphando lubonisa ukuba ukuthatha i-chondroitin sulphate ukuya kuthi ga kwiminyaka emibini kunokunciphisa inkqubela phambili ye-osteoarthritis.
  Olunye uphando luvavanye iziphumo ze-chondroitin sulphate xa ithathwa ngomlomo ngokudibeneyo ne-glucosamine. Olunye uphando lubonisa ukuba ukuthatha iimveliso ezithile eziqukethe i-chondroitin sulfate kunye ne-glucosamine kunceda ukunciphisa iimpawu ze-osteoarthritis. Olunye uphando alubonisi sibonelelo xa kusetyenziswa amalungiselelo angengawo aworhwebo. Ukuthatha i-chondroitin sulfate kunye ne-glucosamine yexesha elide kubonakala ngathi kucothisa ukuqhubela phambili kwe-osteoarthritis.
  Kukho ubungqina bokuba ukhilimu wesikhumba oqukethe i-chondroitin sulphate ngokudibanisa ne-glucosamine sulphate, i-shark cartilage kunye ne-camphor zinokunciphisa iimpawu ze-osteoarthritis. Nangona kunjalo, nakuphi na ukukhululeka kweempawu kunokwenzeka ngenxa yekhamphor hayi ezinye izinto. Akukho phando lubonisa ukuba i-chondroitin ifunxwe eluswini.
  

Akukho bungqina baneleyo bokulinganisa ukusebenza ...

• Intlungu edibeneyo ebangelwa ngamachiza abizwa ngokuba yiaromatase inhibitors (aromatase inhibitor-induction arthralgias). Uphando lwakwangoko lubonisa ukuba ukuthatha indibaniselwano yeglucosamine sulfate kunye ne-chondroitin sulphate kwiidosi ezimbini okanye ezintathu ezahlulwe yonke imihla iiveki ezingama-24 ziphucula iintlungu kunye neempawu ezibangelwa ngamachiza asetyenziselwa ukunyanga umhlaza wamabele.
• Iliso elomileyo. Uphando lwakwangoko lubonisa ukuba ukusebenzisa i-chondroitin sulfate eye eye kunganciphisa amehlo owomileyo. Olunye uphando lubonisa ukuba ukusebenzisa amathontsi wamehlo aqukethe i-chondroitin sulfate kunye ne-xanthan gum kunokuphucula amehlo owomileyo malunga nokusebenzisa iinyembezi. Kodwa olunye uphando lwangaphambili alubonisi sibonelelo.
• Ubuhlungu bemisipha obubangelwa kukuzilolonga. Uphando lwakwangoko lubonisa ukuba ukuthatha i-chondroitin sulphate yonke imihla akukunciphisi ukukhathazeka emva kokuzilolonga emadodeni.
• Ukudumba (ukudumba) kwesisu (gastritis). Uphando lwakwangoko lubonisa ukuba ukusela ulwelo oluthile oluqukethe i-chondroitin sulfate kunye ne-hyaluronic acid kunokunciphisa iintlungu zesisu kubantu abane-gastritis.
• Isifo esibuhlungu sesinyi (i-cystitis yangaphakathi). Olunye uphando lubonisa ukuba ukubeka ulwelo nge-chondroitin sulphate kwisinyi kunokuphucula iimpawu zesinye esibuhlungu. Kodwa uninzi lwezi zifundo zikumgangatho osezantsi. Olunye uphando olukumgangatho ophezulu lubonisa ukuba ukusebenzisa i-chondroitin sulphate ngaphakathi kwisinyi akunoncedo. Olunye uphando lwakwangoko lubonisa ukuba ukuthatha imveliso equlathe i-chondroitin sulfate kunye nezinye izinto ngomlomo kunokuphucula isinyi esibuhlungu. Kodwa akucaci ukuba isibonelelo sivela kwi-chondroitin sulfate okanye ezinye izithako.
• Ukuphazamiseka okuchaphazela amathambo kunye namalungu, ihlala inabantu abanesiphene se-selenium (isifo seKashin-Beck). Uphando lwakwangoko lubonisa ukuba i-chondroitin sulphate, kunye okanye ngaphandle kwe-glucosamine hydrochloride, inokunciphisa iintlungu kubantu abanesifo seKashin-Beck. Kwakhona, ukuthatha i-chondroitin sulphate kunye ne-glucosamine sulphate kunokucothisa indawo edibeneyo yokunciphisa kubantu abanesi sifo samathambo. Nangona kunjalo, akucaci ukuba ukuthatha i-chondroitin sulphate kuphela kunciphisa indawo edibeneyo yokunciphisa.
• Ukuhlaselwa yintliziyo. Olunye uphando lwakwangoko lubonisa ukuba ukuthatha i-chondroitin sulphate ngomlomo kunokunciphisa umngcipheko wokuba nesifo sentliziyo sokuqala okanye esixhaphakileyo.
• I-Scaly, isikhumba esilumkileyo (psoriasis). Uphando lwakwangoko lubonisa ukuba ukuthatha i-chondroitin sulfate kangangeenyanga ezi-2-3 kunciphisa iintlungu kwaye kuphucula imeko zolusu kubantu abane-psoriasis. Kodwa olunye uphando lubonisa ukuba ukuthatha i-chondroitin sulphate (i-Condrosan, i-CS Bio-Active, i-Bioiberica S.A., i-Barcelona, ​​ne-Spain) mihla le kwiinyanga ezi-3 akubunciphisi ubukhali be-psoriasis kubantu abane-psoriasis kunye ne-osteoarthritis.
• Ukuphulukana nolawulo lwesinyi (ukungabikho komchamo). Uphando lwakwangoko lubonisa ukuba ukufaka isodium chondroitin sulphate kwisinyi ngokusebenzisa icatheter yomchamo kuphucula umgangatho wobomi kubantu abane bladder engaphezulu.
• Usulelo lwezintso, isinye, okanye i-urethra (usulelo lwe-urinary tract okanye i-UTIs). Uphando lwakwangoko lubonisa ukuba ukuhambisa isisombululo esine-chondroitin sulfate kunye ne-hyaluronic acid kwisinyi ngokusebenzisa i-catheter kunciphisa inani le-UTIs kwabasetyhini abanembali ye-UTIs.
• Ulusu olugugileyo.
• Isitshisa esiqhubekayo.
• Isifo sentliziyo.
• Cholesterol ephezulu.
• Amathambo abuthathaka kunye nophuko (i-osteoporosis).
• Isikhumba esishwabeneyo.
• Ezinye iimeko.

Ubungqina obungakumbi buyafuneka ukukala i-chondroitin sulfate kwezi zinto zisetyenziswayo.

Kwi-osteoarthritis, intlala kumalungu idilizwa. Ukuthatha i-chondroitin sulphate, enye yeebhloko zokwakha i-cartilage, kunokunciphisa oku kuphazamiseka.

Xa kuthathwa ngomlomo: Chondroitin sulphate yi NGOKUKHUSELEKILEYO. I-Chondroitin sulphate ithathwe ngomlomo ngokukhuselekileyo ukuya kuthi ga kwiminyaka emi-6. Ingabangela iintlungu zesisu kunye nesicaphucaphu. Ezinye iziphumo ebezingalindelekanga ezichaziweyo kukuqunjelwa, urhudo, ukuqhina, intloko ebuhlungu, ukudumba kweenkophe, ukudumba kwemilenze, ukulahleka kweenwele, irhashalala, kunye nokubetha kwentliziyo okungaqhelekanga.

Xa ubekwe kwiliso: Chondroitin sulphate yi NGOKUKHUSELEKILEYO xa isetyenziswa njengesisombululo seso ngexesha lotyando lwamehlo.

Xa unikezwe ngokudutyulwa: Chondroitin sulphate yi UKHUSELEKO OLUNOKWENZEKA xa utofelwe kwimisipha njengefoto, ixesha elifutshane.

Kukho inkxalabo malunga nokhuseleko lwe-chondroitin sulphate kuba ivela kwimithombo yezilwanyana. Abanye abantu banexhala lokuba ukwenziwa kweendlela ezingakhuselekanga kunokukhokelela kungcoliseko lweemveliso ze-chondroitin ezinezihlunu zezilwanyana ezigulayo, kubandakanya nezo zinokuhambisa isifo se-spongiform encephalopathy (isifo seenkomo). Ukuza kuthi ga ngoku, akukho ngxelo ze-chondroitin zibangela isifo ebantwini, kwaye umngcipheko ucingelwa ukuba uphantsi.

Ezinye iimveliso ze-chondroitin ziqulathe inani elingaphezulu kwemanganizi. Buza umsebenzi wakho wezempilo malunga neempawu ezithembekileyo.

Amanyathelo okhuseleko kunye nezilumkiso:

Ukukhulelwa kunye nokuncancisa: Akukho lwazi lwaneleyo lunokuthenjwa lokwazi ukuba i-chondroitin sulphate ikhuselekile ukusetyenziswa xa ukhulelwe okanye uncancisa. Hlala kwicala elikhuselekileyo kwaye uphephe ukusetyenziswa.

Isifo sombefu: Kukho inkxalabo yokuba i-chondroitin sulphate inokusenza mandundu isifuba. Ukuba une-asthma, sebenzisa i-chondroitin sulfate ngononophelo.

Ukuphazamiseka kwegaziKwithiyori, ukulawula i-chondroitin sulphate kunokunyusa umngcipheko wokopha kubantu abanengxaki yokunqanda igazi.

Umhlaza wedlala lobudoda: Uphando lwakwangoko lubonisa ukuba i-chondroitin inokubangela ukusasazeka okanye ukuphindaphindeka komhlaza webele. Esi siphumo asiboniswanga ngezongezo ze-chondroitin sulphate. Nangona kunjalo, de kube kwaziwa ngakumbi, musa ukuthatha i-chondroitin sulphate ukuba unomdlavuza wesibeletho okanye usemngciphekweni omkhulu wokukhula (unomntakwenu okanye utata onomdlavuza wesibeletho).

Iphakathi

Lumka ngale nhlanganisela.

IWarfarin (Coumadin)

IWarfarin (Coumadin) isetyenziselwa ukucothisa ukujiya kwegazi. Kukho iingxelo ezininzi ezibonisa ukuba ukuthatha i-chondroitin kunye ne-glucosamine kwonyusa isiphumo se-warfarin (Coumadin) ekwenziweni kwegazi. Oku kunokubangela ukugruzuka nokopha okunokuba kubi kakhulu. Musa ukuthatha i-chondroitin ukuba uthatha i-warfarin (Coumadin).

Akukho kunxibelelana kwaziwayo kunye namayeza kunye nezongezo.

Akukho kunxibelelana kwaziwayo nokutya.

La machiza alandelayo afundwe kuphando lwezesayensi:

NGOMLOMO:

• Kwi-osteoarthritis: Umthamo oqhelekileyo we-chondroitin sulphate yi-800-2000 mg ethathwe njengedosi enye okanye kumanani amabini okanye amathathu ahlukeneyo mihla le ukuya kuthi ga kwiminyaka emi-3.

Ukufaka isicelo kulusu:

• Kwi-osteoarthritisIkhrimu ene-50 mg / gram ye-chondroitin sulfate, 30 mg / gram yeglucosamine sulfate, 140 mg / gram ye-shark cartilage, kunye ne-32 mg / gram yekhamphor isetyenzisiwe njengoko kufuneka kumalungu abuhlungu ukuya kuthi ga kwiiveki ezisibhozo.

UKUFUTSHWA KWISIHLULELA:

• Kwi-osteoarthritis: I-Chondroitin sulfate (Matrix) iye yatofwa kwimisipha yonke imihla okanye kabini ngeveki kwiinyanga ezi-6.

ISICELO ESENZIWA KWILO:

• Ngamehlo: Amaconsi wamehlo ohlukeneyo aqukethe isodium hyaluronate kunye ne chondroitin sulfate (DisCoVisc, Alcon Laboratories; Viscoat, Alcon Laboratories; DuoVisc, Alcon Laboratories; Viscoat, Alcon Laboratories; Provisc, Alcon Laboratories) zisetyenzisiwe ngexesha lotyando lwamehlo.

Chondroitin Sulfate A, Chondroitin Sulfate A, Chondroitin Sulfate A, Chondroitin Sulfate B, Chondroitin Sulfate, Chondrootin Sulphates, Chondroitin Sulphates, Chondroetin Sulphates, Chondroitin Sulphates, Chondroitin Sulphate, Chondroitin Sulphate, Chondroitin Sulphate, Chondroitin Sulphate, Chondroitin Sulphate, , IChondroïtine 4-Sulfate, Chondroïtine 4- et 6- Sulfate, Condroitin, CPS, CS, CSA, CSC, GAG, Galactosaminoglucuronoglycan Sulfate, Chondroitin 4-Sulfate, Chondroitin 4- kunye ne-6-Sulfate, Poly- (1-> 3) -N-Aceltyl-2-Amino-2-Deoxy-3-O-Beta-D-Glucopyranurosyl-4- (okanye 6-), Polysulfate de Chondroïtine, Sulfate de Chondroïtine, Sulfate de Galactosaminoglucuronoglycane, Sulfates de Chondroïtine, Sulfato de Chondroïtine .

Ukuze ufunde okungakumbi malunga nokubhalwa kweli nqaku, nceda ubone Amayeza endalo aVimba weDatha indlela yokusebenza.

1. UBruyere O, Honvo G, uVeronese N, et al. Ingcebiso ehlaziyiweyo ye-algorithm yokulawulwa kwamadolo e-osteoarthritis kuMbutho waseYurophu woNyango lwezoNyango kunye nezoQoqosho lweOsteoporosis, Osteoarthritis, kunye neMisculoskeletal Disease (ESCEO). Isemina iRheum yeArthritis. NgoDisemba ka-2019; 49: 337-50. Jonga i-abstract.
2. I-Navarro SL, umrhumo L, uCurtis KR, uLampe JW, uHullar MAJ. Ukumodareyithwa kweGut Microbiota yiGlucosamine kunye neChondroitin kuLingo oluQhelekileyo, oluMfama oLungeloukuBala ebantwini. Amagciwane. 2019 Novemba 23; 7. IPH: E610. Jonga i-abstract.
3. Ukugcina i-OF, Finamore R, Stellavato A, et al. I-chondroitin sulphate yaseYurophu kunye neglucosamine yokutya: Umgangatho wenkqubo kunye novavanyo lobungakanani xa kuthelekiswa namayeza. ICarhydr Polym. 2019 Oktobha 15; 222: 114984. Jonga i-abstract.
4. IKolasinski SL, uNeogi T, iHochberg MC, et al. I-2019 American College yeRheumatology / Isiseko seArthritis Isikhokelo solawulo lwe-osteoarthritis yesandla, inyonga, kunye nedolo. Isifo samathambo Rheumatol. NgoFebruwari 2020; 72: 220-33. Jonga i-abstract.
5. I-Savarino V, Isantya F2, iSparpignato C; Iqela lokuFunda le-Esoxx. Ulingo lwezonyango olungenamsebenzi: ukhuseleko lwe-mucosal kunye nokudityaniswa kwe-asidi kunyango lwesifo se-reflux esingasebenziyo-ukusebenza kwe-Esoxx, i-hyaluronic acid-chondroitin sulphate esekwe kubume bokubopha. Ndlela Pharmacol Ther. Ngo-2017; 45: 631-642. Jonga i-abstract.
6. UGoddard JC, uJanssen DAW. Ukungena ngaphakathi kwe-hyaluronic acid kunye ne-chondroitin sulphate yokufumana usulelo rhoqo kumchamo: uphononongo lwenkqubo kunye nohlalutyo lweemeta. I-Ur Urynynecol J. 2018 Julayi; 29: 933-942. Epub 2017 Novemba 27. Ukuphononongwa. Jonga i-abstract.
7. U-Iannitti T, uMorales-Medina JC, uMerighi A, et al. Isixhobo sonyango esisekwe kwi-hyaluronic acid- kunye ne-chondroitin sulphate siphucula iintlungu zesisu, ukungakhululeki, kunye neempawu ze-endoscopic. Ukuhambisa iziyobisi kuguqulwe. Ngo-2018 Oktobha; 8: 994-999. Jonga i-abstract.
8. I-Tsuruta A, Horiike T, Yoshimura M, Nagaoka I. Uvavanyo lwesiphumo solawulo lwe-glucosamine equlathe isongezelelo kwii-biomarkers ze-cartilage metabolism kubadlali bebhola ekhatywayo: Isifundo esilawulwa ngokungahleliwe. Mol Mol Rep. 2018 Okt; 18: 3941-3948. Epub 2018 Aug 17. Jonga i-abstract.
9. Efanayo-Mendía M, Sánchez-García A, Vilchez-Cavazos F, Acosta-Olivo CA, Peña-Martínez VM, Simental-Mendía LE. Iziphumo ze-glucosamine kunye ne-chondroitin sulfate kwiimpawu zedolo le-osteoarthritis: uphononongo olucwangcisiweyo kunye nohlalutyo lweemeta lwezilingo ezilawulwa ngokungenamthetho. IRheumatol Int. 2018 Agasti; 38: 1413-1428. Epub 2018 Jun 11. Ukuphononongwa. Jonga i-abstract.
10. U-Ogata T, u-Ideno Y, u-Akai M, et al. Iziphumo ze-glucosamine kwizigulana ezine-osteoarthritis emadolweni: uphononongo lwenkqubo kunye nohlalutyo lweemeta. KwiKlinikhi yaseRheumatol. 2018 Sep; 37: 2479-2487. Epub 2018 Epreli 30. Jonga i-abstract.
11. IPyo JS, Cho WJ. Uvandlakanyo olucwangcisiweyo kunye neMeta-Uhlalutyo lwe-Intravesical Hyaluronic Acid kunye neHyaluronic Acid / Chondroitin Sulfate Instillation ye-Interstitial Cystitis / Painful Bladder Syndrome. Iselfowuni yePhysol Biochem. Ngo-2016; 39: 1618-25. Jonga i-abstract.
12. I-Lopez HL, iZiegenfuss TN, iPark J.Uvavanyo lweZiphumo zeBioCell Collagen, iNoveli yeCartilage Extract, kwiNkxaso yeeTishu eziDibeneyo kunye nokuBuya ngokuSebenzayo kuMthambo. Umdibaniso weMed (Encinitas). 2015; 14: 30-8. Jonga i-abstract.
13. UPérez-Balbuena AL, u-Ochoa-Tabares JC, uBelalcazar-Rey S, et al. Ukuchaneka Ukusebenza kwendibaniselwano esisigxina ye-0.09% xanthan gum / 0.1% chondroitin sulfate preservative free vs polyethylene glycol / propylene glycol kwizifundo ezinezifo ezomileyo zamehlo: isilingo esilawulwa ngokungahleliwe. I-BMC yeOphthalmol. Ngo-2016 Sep; 16: 164.Jonga i-abstract.
14. UZeng C, Wei J, Li H, okqhubekayo. Ukusebenza kunye nokukhuseleka kweGlucosamine, chondroitin, zombini ngokudibeneyo, okanye i-celecoxib kunyango lwe-osteoarthritis emadolweni. Inzululwazi. 2015; 5: 16827. Jonga i-abstract.
15. I-Roman-Blas JA, i-Castañeda S, iSánchez-Pernaute O, et al. Ukuchaneka Unyango oluHlanganisiweyo kunye neChondroitin Sulfate kunye neGlucosamine Sulfate ayibonisi bume bungaphezulu kwePlacebo yokuNcitshiswa kweNtlungu eHlanganisiweyo kunye nokuSebenza okuSebenzayo kwizigulana ezine-Knee Osteoarthritis: Iinyanga eziNtandathu zeMulticenter, iRandomised, Double-Blind, Placebo-Controlled Clinical Trial. Isifo samathambo Rheumatol. Ngo-2017; 69: 77-85. Jonga i-abstract.
16. UPelletier JP, uRaynauld JP, uBeaulieu AD, okqhubekayo. Ukusebenza kweChondroitin sulphate ngokuchasene ne-celecoxib kumadolo e-osteoarthritis utshintsho olwakhiweyo kusetyenziswa imaging yemagneti yokujonga: isifundo seminyaka emi-2 yokuhlola. Isifo seArthritis Res. Ngo-2016; 18: 256. Jonga i-abstract.
17. USingh JA, uNorbaloochi S, uMacDonald R, uMaxwell LJ. I-Chondroitin ye-osteoarthritis. Isiseko sedatha yeCochrane Isityhi sika-2015 ngoJanuwari 28; 1: CD005614. Jonga i-abstract.
18. UBruyère O, Cooper C, uPelletier JP, et al. Isiteyitimenti sokuvumelana kwi-European Society ye-Clinical and Economic Aspects ye-Osteoporosis kunye ne-Osteoarthritis (ESCEO) algorithm yokulawulwa kwamadolo e-osteoarthritis-Ukusuka kumayeza asekwe kubungqina kubomi bokwenyani. Isemina iRheum yeArthritis. Ngo-2016; 45 (4 iSuppl): S3-11. Jonga i-abstract.
19. I-Reginster JY, i-Dudler J, i-Blicharski T, i-Pavelka K. i-Chondroitin sulphate ye-Pharmaceutical iyasebenza njenge-celecoxib kwaye iphezulu kwi-placebo kwi-osteoarthritis ephawulekayo: i-ChONdroitin kunye ne-CElecoxib kunye ne-Placebo Trial (CONCEPT). U-Ann Rheum Dis. Ngo-2017 ngoMeyi 22. pii: annrheumdis-2016-210860. Jonga i-abstract.
20. IVolpi N. Umgangatho wamalungiselelo e-chondroitin sulfate ahlukeneyo ngokunxulumene nomsebenzi wabo wokunyanga. J Pharm Pharmacol 2009; 61: 1271-80. Jonga i-abstract.
21. Umxhasi RM. I-Chondroitin sulphate: imolekyuli entsonkothileyo enefuthe elinokubakho kuluhlu olubanzi lweenkqubo zebhayoloji. Gcwalisa iTher Med ngo-2009; 17: 56-62. Jonga i-abstract.
22. UBarnhill JG, uFye CL, uWilliam DW, uReda DJ, uHarris CL, uClegg DO. Ukhetho lwemveliso yeChondroitin yeglucosamine / chondroitin isifo samathambo sokungenelela. J Ndingu-Pharm Assoc 2006; 46: 14-24. Jonga i-abstract.
23. Zegels B, Crozes P, Uebelhart D, Bruyère O, Reginster JY. Ukulingana kwethamo elinye (1200 mg) ngokuthelekiswa nexesha kathathu ngosuku (400 mg) ye-chondroitin 4 & 6 sulfate kwizigulana ezinedolo le-osteoarthritis. Iziphumo zophononongo olulawulwayo olungenamakhonkco kabini. I-Osteoarthritis Cartilage 2013; 21: 22-7. Jonga i-abstract.
24. I-Vigan M. Allergic contact dermatitis ebangelwa yi-sodium chondroitin sulfate equlethwe kukuthambisa. Nxibelelana neDermatitis 2014; 70: 383-4. Jonga i-abstract.
25. UTorella M, Schettino MT, uSalvatore S, uSerati M, uDe Franciscis P, uColacurci N. Unyango lwe-intravesical kwi-cystitis ephindaphindayo: amava eendawo ezininzi. J Ukosulela uChemother 2013; 19: 920-5. Jonga i-abstract.
26. Schneider H, Maheu E, Cucherat M.Umphumo wokuguqula impawu ye-chondroitin sulphate kwi-knee osteoarthritis: uhlalutyo lweemeta lwezilingo ezilawulwa ngokungahleliwe ezenziwa nge-structum (®). Vula iRheumatol J. 2012; 6: 183-9. Jonga i-abstract.
27. I-Palmieri B, iMerighi A, iCorbascio D, iRottigni V, iFistetto G, i-Esposito A.Umdibaniso olungelelanisiweyo we-hyaluronic acid kunye ne-chondroitin-sulphate yokwenziwa ngomlomo kwimfama ephindwe kabini engacaciswanga, elawulwa yi-placebo kunyango lweempawu kwizigulana ezine-gastroesophageal Reflux. I-Eur Rev Med ye-Pharmacol Sci 2013; 17: 3272-8. Jonga i-abstract.
28. ILlamas-Moreno JF, iBaiza-Durán LM, iSauceo-Rodríguez LR, iAlaníz-De la O JF. Ukusebenza kunye nokukhuseleka kwe-chondroitin sulphate / i-xanthan gum xa kuthelekiswa ne-polyethylene glycol / propylene glycol / hydroxypropyl guar kwizigulana ezineliso elomileyo. Iiklinikhi ze-Ophthalmol 2013; 7: 995-9. Jonga i-abstract.
29. UDe Vita D, uAntell H, uGiordano S.Ukusebenza kwe-asidi ye-hyaluronic acid kunye okanye ngaphandle kwe-chondroitin sulphate ye-cystitis ebangelwa yintsholongwane kubafazi abadala: uhlalutyo lweemeta. I-Ur Urynynecol J 2013; 24: 545-52. Jonga i-abstract.
30. UGreenlee H, uCrew KD, uShao T, uKranwinkel G, uKalinsky K, uMaurer M, uBrafman L, u-Insel B, u-Tsai WY, uHershman DL. Isigaba sesi-II sokufunda nge-glucosamine ene-chondroitin kwi-aromatase inhibitor enxulumene neempawu zokudibana kwabasetyhini abanomhlaza wamabele. Inkxaso yoMhlaza woNyango 2013; 21: 1077-87. Jonga i-abstract.
31. UFransen M, Agaliotis M, Nairn L, Votrubec M, Bridgett L, Su S, Jan S, Matshi L, Edmonds J, Norton R, Woodward M, Usuku R; Iqela le-LEGS lokufunda ngokubambisana. I-Glucosamine kunye ne-chondroitin yamadolo e-osteoarthritis: uvavanyo lweklinikhi olulawulwa ngokujonga ulwahlulo lwe-placebo kuvavanyo lweerimens enye kunye nokudibanisa. UAnn Rheum Dis 2015; 74: 851-8. Jonga i-abstract.
32. Provenza JR, Shinjo SK, Silva JM, Peron CR, kunye noRocha FA. I-glucosamine edibeneyo kunye ne-chondroitin sulfate, kube kanye okanye kathathu imihla ngemihla, ibonelela nge-analgesia efanelekileyo yezonyango kwi-knee osteoarthritis. Iiklinikhi zeRheumatol 2015; 34: 1455-62.
33. von Felden J, Montani M, Kessebohm K, Stickel F.Ukulimala kwesibindi okunyanzelekileyo okuxelisa i-hepatitis emva kokutya izongezo zokutya ezine-glucosamine kunye ne-chondroitin sulfate. I-Int J Clin Pharmacol Ther 2013; 51: 219-23. Jonga i-abstract.
34. IHochberg MC, uMartel-Pelletier J, uMonfort J, uMöller I, uCastillo JR, uArden N, uBerenbaum F, uBlanco FJ, uConaghan PG, uDoménech G, uHenrotin Y, uPap T, uRichette P, uSawitzke A, uDu Souich P, uPelletier JP ; egameni leQela loPhando. Idibeneyo ye-chondroitin sulphate kunye ne-glucosamine ye-osteoarthritis ebuhlungu yamadolo: i-multicentre, i-randomized, i-blind-blind, i-non-inferiority trial kunye ne-celecoxib. UAnn Rheum Dis 2016; 75: 37-44. Jonga i-abstract.
35. ICerda C, Bruguera M, Parés A.Hepatotoxicity enxulunyaniswa ne-glucosamine kunye ne-chondroitin sulphate kwizigulana ezinesifo esinganyangekiyo sesibindi. Ihlabathi J Gastroenterol 2013; 19: 5381-4. Jonga i-abstract.
36. UBray HG, uGregory JE, uStacey M. Chemistry yeeTishu. 1. IChondroitin evela kwintlala. Ibhayiloji J 1944; 38: 142-146.
37. I-FDA. Ukuvunywa kwangaphambili (PMA). Ifumaneka kwi: http://www.accessdata.fda.gov/script/cdrh/cfdocs/cfpma/pma.cfm?id=20196.
38. I-FDA izibonelelo zokuvunywa kwangaphambili kweViscoat. Imigangatho yoKhuseleko yeBiomed 1986; 16: 82.
39. U-Blotman F kunye no-Loyau G. Uvavanyo lwezonyango kunye ne-chondroitin sulfate kwi-gonarthrosis [abstract]. I-Osteoarthritis Cart ngo-1993; 1: 68.
40. Adebowale AO, Cox DS Liang Z Eddington ND. Uhlalutyo lwe-glucosamine kunye nomxholo we-chondroitin sulphate kwiimveliso ezithengisiweyo kunye ne-caco-2 permeability yezinto ze-chondroitin sulfate. J Ndingu-Assoc weNutraceutical. Ngo-2000; 3: 37-44.
41. Pavelka kunye et al. Imfama kabini, isiphumo sokufunda ngomlomo we-cs 4 & 6 1200mg, 800mg, 200mg ngokuchasene ne-placebo kunyango lwe-femorotibial osteoarthritis. IWular Rheumatol Liter 1998; 27 (suppl 2): ​​63.
42. U-L'Hirondel JL. [Uphononongo lwezonyango oluyimfama kabini olwenziwa ngomlomo nge-chondroitin sulphate ngokuchasene ne-placebo kunyango lwe-tibio femoral gonarthrosis kwizigulana ezili-125]. I-Litera Rheumatologica 1992; 14: 77-84.
43. UFleisch, AM, uMerlin C, u-Imhoff A, kunye no-al. Isifundo sonyaka omnye esingenamntu, esingaboniyo, esilawulwa yi-placebo kunye ne-chondroitin sulfate yomlomo kwizigulana ezinedolo le-osteoarthritis. I-Osteoarthritis kunye neCartilage 1997; 5: 70.
44. Uebelhart D kunye noChantraine A. I-Efficacite clinique du sulfate de chondroitine dans la gonarthrose: Etude randomisee en double-insu versus placebo [abstract]. UMfu Rhumatisme 1994; 10: 692.
45. I-Verbruggen, G., Goemaere, S., kunye neVeys, E. M. Chondroitin sulphate: S / DMOAD (ulwakhiwo / isifo esiguqula ichiza le-anti-osteoarthritis) kunyango lwe-OA yomnwe. I-Osteoarthritis Cartilage 1998; I-6 Suppl A: 37-38. Jonga i-abstract.
46. I-Nakazawa, K., Murata, K., Izuka, K., kunye no-Oshima, Y. Iziphumo zexesha elifutshane ze-chondroitin sulfates A kunye no-C kwizifundo ze-coronary atherosclerotic: Ngokubhekiselele kwimisebenzi yayo yokulwa ne-thrombogenic. Intliziyo J 1969; 10: 289-296. Jonga i-abstract.
47. I-Nakazawa, K. kunye neMurata, K.Ukuthelekisa isifundo se-chondroitin sulphate isomers kwizifundo ze-atherosclerotic. ZFA. Ngo-1979; 34: 153-159. Jonga i-abstract.
48. Thilo, G. [Uphononongo lwamatyala angama-35 e-arthrosis anyangwa nge-chondrotiine sulfuric acid (umbhali uguqulela)]. ISchweizerische Rundschau fur Medizin Praxis 12-27-1977; 66: 1696-1699. Jonga i-abstract.
49. Uxinzelelo lwe-postoperative emva kwe-phacoemulsification: i-sodium hyaluronate vs sodium chondroitin sulfate-sodium hyaluronate. UAnn Ophthalmol. Ngo-1989; 21: 85-88, 90.
50. Railhac, JJ, Zaim, M., Saurel, AS, Vial, J., kunye no-Fournie, B. Iziphumo zonyango lweenyanga ezili-12 kunye ne-chondroitin sulphate kumthamo we-cartilage kwizigulana zamadolo e-osteoarthritis: umqhubi olawulwa yi-placebo ukufunda usebenzisa iMRI. KwiKlinikhi eRheumatol. Ngo-2012; 31: 1347-1357. Jonga i-abstract.
51. De, Vita D. kunye noGiordano, S. Ukusebenza kwe-hyaluronic acid / chondroitin sulfate ye-intravesical kwi-cystitis yebacteria ephindaphindayo: isifundo esingahleliwe. Int. Urogynecol. J. Ngo-2012; 23: 1707-1713. Jonga i-abstract.
52. I-Nickel, i-JC, i-Hanno, i-P., I-Kumar, i-K, ne-Thomas, i-H.I-multicenter yesibini, i-randomized, i-blind-blind, i-parallel-group vavanyo lwempumelelo kunye nokukhuseleka kwe-intravesical sodium chondroitin sulfate xa kuthelekiswa nokulawulwa kwezithuthi ezingasebenziyo kwizifundo nge-interstitial isifo se-cystitis / bladder syndrome. Urology 2012; 79: 1220-1224 (PubMed) (Umnqamlezo) Jonga i-abstract.
53. Yue, J., Yang, M., Yi, S., Dong, B., Li, W., Yang, Z., Lu, J., Zhang, R., kunye no-Yong, J. Chondroitin sulphate kunye / okanye I-glucosamine hydrochloride yesifo seKashin-Beck: isifundo esilawulwa liqela, elilawulwa yi-placebo. I-Osteoarthritis. Ngo-2012; 20: 622-629. Jonga i-abstract.
54. I-Kanzaki, N., Saito, K., Maeda, A., Kitagawa, Y., Kiso, Y., Watanabe, K., Tomonaga, A., Nagaoka, I., kunye no Yamaguchi, H. Iziphumo zesongezelelo sokutya. Equkethe i-glucosamine hydrochloride, i-chondroitin sulfate kunye ne-quercetin glycosides kwiimpawu zedolo le-osteoarthritis: isifundo esilawulwa ngokungahleliwe, esingaboniyo, esilawulwa yi-placebo. Ukutya okuLimo kweJ. I-3-15-2012; 92: 862-869. Jonga i-abstract.
55. UWildi, uLM, uRaynauld, JP, uMartel-Pelletier, uJ, uBeaulieu, A., uBessette, uL, uMorin, uF, uAbram, uF, uDorais, uM, noPelletier, uJP Chondroitin sulphate unciphisa umthamo we-cartilage ukulahleka kunye nezilonda zomongo wethambo kwizigulana zamadolo e-osteoarthritis eziqala kwangoko kwiinyanga ezi-6 emva kokuqaliswa konyango: isifundo somqhubi esilawulwa ngokungahleliwe, esingaboniyo, esilawulwa yi-placebo sisebenzisa iMRI. U-Ann. Ukuhlaziya. Ngo-2011; 70: 982-989. Jonga i-abstract.
56. UDamiano, R., Quarto, G., Bava, I., Ucciero, G., De, Domenico R., Palumbo, MI, kunye no-Autorino, R. Uthintelo losulelo oluphindaphindeneyo lomchamo ngokulawulwa kwe-hyaluronic acid kunye ne-chondroitin sulphate Uvavanyo olulawulwa ngokungenamthetho lwe-placebo. Uurol. Ngo-2011; 59: 645-651. Jonga i-abstract.
57. UZhou, Q., Chen, H., Qu, M., Wang, Q., Yang, L., kunye noXie, L. Uphuhliso lwenoveli ex vivo yemodeli yokubambelela kwefungus. Ingcwaba leArch.Clin. Exp. IOphthalmol. Ngo-2011; 249: 693-700. Jonga i-abstract.
58. I-Liesegang, T. J. Viscoelastic yezinto kwi-ophthalmology. Ukusinda kwiOphthalmol. Ngo-1990; 34: 268-293. Jonga i-abstract.
59. Furer, V., Wieczorek, R.L, kunye noPillinger, M.H Bilateral pinna chondritis eyandulelwa kukuqaliswa kokongeza kweglucosamine chondroitin. Iscand. J. Rheumatol. Ngo-2011; 40: 241-243. Jonga i-abstract.
60. Chen, W., Yao, C., Chu, I.M, no Wei, Y.H Thelekisa iimpembelelo ze-chondrogenesis ngenkcubeko yeeseli zemeschch zeseli ezinentlobo ezahlukeneyo ze-chondroitin sulphate C. J. Biosci. Bioeng. Ngo-2011; 111: 226-231. Jonga i-abstract.
61. Kato, D., Era, S., Watanabe, I., Arihara, M., Sugiura, N., Kimata, K., Suzuki, Y., Morita, K., Hidari, KI, kunye no-Suzuki, T. Antiviral. Umsebenzi we-chondroitin sulphate E ojolise kwiproteni yemvulophu yentsholongwane. Intsholongwane. Ngo-2010; 88: 236-243. Jonga i-abstract.
62. UWandel, S., Juni, P., Tendal, B., Nuesch, E., Villiger, PM, Welton, NJ, Reichenbach, S., kunye noTrelle, S. Iziphumo ze-glucosamine, chondroitin, okanye i-placebo kwizigulana ezine-osteoarthritis. okhalweni okanye idolo: uhlalutyo lweemeta zenethiwekhi. BMJ 2010; 341: c4675. Jonga i-abstract.
63. Rentsch, C., Rentsch, B., Breier, A., Spekl, K., Jung, R., Manthey, S., Scharnweber, D., Zwipp, H., kunye neBiewener, A. Ithambo elide libalulekile- ubungakanani beziphene ziphathwe nge-scaffolds ye-polycaprolactone-co-lactide scaffolds eyenzelwe izicwili: isifundo somqhubi kwiigundane. UJ, waBhala.Mater.Res.A 12-1-2010; 95: 964-972. Jonga i-abstract.
64. Im, A. R., Park, Y., kunye noKim, Y. S. Ukuqhawulwa kunye nokubonakaliswa kwe-chondroitin sulfates kwi-sturgeon (Acipenser sinensis) kunye neziphumo zazo ekukhuleni kwe-fibroblasts. Biol.Umveliso.Inkunzi yenkomo. Ngo-2010; 33: 1268-1273. Jonga i-abstract.
65. ISawitzke, AD, Shi, H., Finco, MF, Dunlop, DD, Harris, CL, Singer, NG, Bradley, JD, Isilivere, D., Jackson, CG, Lane, NE, Oddis, CV, Wolfe, F. , Lisse, J., Furst, DE, Bingham, CO, Reda, DJ, Moskowitz, RW, Williams, HJ, kunye noClegg, NGOKUQINISEKISA ukusebenza konyango kunye nokhuseleko lwe-glucosamine, i-chondroitin sulphate, indibaniselwano yabo, i-celecoxib okanye i-placebo ethathiweyo ukunyanga i-osteoarthritis edolweni: Iziphumo zeminyaka emi-2 ezivela kwi-GAIT. U-Ann. Ukuhlaziya. Ngo-2010; 69: 1459-1464. Jonga i-abstract.
66. I-Nickel, i-JC, i-Egerdie, i-RB, i-Steinhoff, i-G, i-Palmer, i-B, ne-Hanno, i-P.Ukuvavanywa kokusebenza kunye nokhuseleko lwe-intravesical sodium chondroitin sulphate ngokuchasene nolawulo lwezithuthi abaguli abane-cystitis / isifo esibuhlungu sesinyi. Urology 2010; 76: 804-809. Jonga i-abstract.
67. UMoller, I., Perez, M., Monfort, J., Benito, P., Cuevas, J., Perna, C., Domenech, G., Herrero, M., Montell, E., kunye noVerges, uJ. Ukusebenza kwe-chondroitin sulphate kwizigulana ezinedolo le-osteoarthritis kunye ne-psoriasis: isifundo esilawulwa ngokungahleliwe, esingaboniyo, esilawulwa yi-placebo. I-Osteoarthritis. Ngo-2010; 18 ISuppl 1: S32-S40. Jonga i-abstract.
68. I-Egea, J., Garcia, A. G., Verges, J., Montell, E., kunye neLopez, M. G. Antioxidant, antiinflammatory kunye neuroprotective yezenzo ze-chondroitin sulfate kunye neeproteoglycans. I-Osteoarthritis. 2010; 18 Isixhobo 1: S24-S27. Jonga i-abstract.
69. I-Hochberg, M. C. Ulwakhiwo-lokuguqula iziphumo ze-chondroitin sulphate kwi-osteoarthritis yedolo: uhlalutyo oluhlaziyiweyo lwe-meta-uhlalutyo lwezilingo ezilawulwa ngokungahleliwe ze-2-year-term. I-Osteoarthritis. 2010; 18 Isixhobo 1: S28-S31. Jonga i-abstract.
70. Imada, K., Oka, H., Kawasaki, D., Miura, N., Sato, T., kunye no-Ito, A. Iindlela zokulwa ne-arthritic ze-chondroitin sulphate yendalo kwii-chondrocyte ze-articular kunye ne-synovial fibroblasts. Biol. Inzululwazi yezeNkomo. Ngo-2010; 33: 410-414. Jonga i-abstract.
71. I-Pavelka, K., Coste, P., Geher, P., kunye neKrejci, G. Ukusebenza kunye nokhuseleko lwe-piascledine 300 ngokuchasene ne-chondroitin sulphate kunyango lweenyanga ezi-6 kunye nokujongwa kweenyanga ezi-2 kwizigulana ezine-osteoarthritis yamadolo. KwiKlinikhi eRheumatol. Ngo-2010; 29: 659-670. Jonga i-abstract.
72. UTat, S. K., Pelletier, J. P., Mineau, F., uDuval, N., kunye noMartel-Pelletier, J. Iziphumo ezahluka-hlukeneyo ze-3 ezahlukeneyo ze-chondroitin sulphate compounds kwi-osteoarthritic cartilage / chondrocytes: ukubaluleka kokucoceka kunye nenkqubo yemveliso. UJ. Rheumatol. Ngo-2010; 37: 656-664. Jonga i-abstract.
73. I-Lane, S. S., Naylor, D. W., Kullerstrand, L. J., Knauth, K., kunye neLindstrom, R. L. Ukuthelekiswa okulindelekileyo kweziphumo ze-Occucoat, Viscoat, kunye neHelalon kuxinzelelo lwe-intraocular kunye ne-endothelial cell cell. J Cataract Refract. Utyando. Ngo-1991; 17: 21-26. Jonga i-abstract.
74. UJackson, CG, Plaas, AH, Sandy, JD, Hua, C., Kim-Rolands, S., Barnhill, JG, Harris, CL, kunye noClegg, DO I-pharmacokinetics yomntu yokufakwa ngomlomo kweglucosamine kunye ne-chondroitin sulfate ethathwe ngokwahlukeneyo okanye ngokudibeneyo. I-Osteoarthritis Cartilage 2010; 18: 297-302. Jonga i-abstract.
75. Mnyama, C., Clar, C., Henderson, R., MacEachern, C., McNamee, P., Quayyum, Z., Royle, P., noTomas, S.Ukusebenza kweklinikhi kweglucosamine kunye ne-chondroitin yongeza okanye ukubamba ukuqhubela phambili kwe-osteoarthritis emadolweni: uphononongo olucwangcisiweyo kunye novavanyo lwezoqoqosho. Itekhnoloji yezeMpilo. Ngo-2009; 13: 1-148. Jonga i-abstract.
76. I-Sasisekharan, R. kunye ne-Shriver, Z. Ukusuka kwingxaki ukuya kwithuba: umbono kwingxaki ye-heparin. Ukuhluza. Ngo-2009; 102: 854-858. Jonga i-abstract.
77. ICrowley, DC, Lau, FC, Sharma, P., Evans, M., Guthrie, N., Bagchi, M., Bagchi, D., Dey, DK, kunye noRaychaudhuri, ukhuseleko lwe-SP kunye nokusebenza kohlobo olungafakwanga lwe-II collagen kwi unyango lwe-osteoarthritis emadolweni: uvavanyo lwezonyango. Int.J.Med.Sci. Ngo-2009; 6: 312-321. Jonga i-abstract.
78. IRainsford, K. D. Ukubaluleka kokudityaniswa kwamayeza kunye nobungqina obuvela kuvavanyo lweklinikhi kunye nezifundo ze-pharmacological ekumiseleni ukusebenza kwe-chondroitin sulphate kunye nezinye i-glycosaminoglycans: i-critique. J. Ipharm. IPharmacol. Ngo-2009; 61: 1263-1270. Jonga i-abstract.
79. Hauser, P.J, Buethe, D. A., Califano, J., Sofinowski, T. M., Culkin, D., noHurst, R. E. Ukubuyisela umsebenzi wesithintelo kwi-asidi eyonakele isinyi nge-intravesical chondroitin sulfate. J. Urol. Ngo-2009; 182: 2477-2482. Jonga i-abstract.
80. UKubo, M., Ando, ​​K., Mimura, T., Matsusue, Y., kunye no-Mori, K. Inzululwazi yoBomi. I-9-23-2009; 85 (13-14): 477-483. Jonga i-abstract.
81. Lee, YH, Woo, J.H, Choi, S.J, Ji, J. D., kunye neNgoma, G.G.Iziphumo ze-glucosamine okanye i-chondroitin sulfate ekuqhubekeni kwe-osteoarthritis: uhlalutyo lweemeta. IRheumatol Int 2010; 30: 357-363. Jonga i-abstract.
82. du Souich, P., Garcia, A. G., Verges, J., and Montell, E.Iziphumo zokuchasana nokuchasana ne-chondroitin sulphate. J. Cell Mol. Isixhobo. 2009; 13 (8A): 1451-1463. Jonga i-abstract.
83. UFthenou, E., Zong, F., Zafiropoulos, A., Dobra, K., Hjerpe, A., kunye noTzanakakis, G. N. Chondroitin sulphate A ilawula ukunamathela kweseli ye-fibrosarcoma, ukuhamba kunye nokuhamba ngendlela ye-JNK kunye ne-tyrosine kinase ebonisa indlela. KwiVivo 2009; 23: 69-76. Jonga i-abstract.
84. I-Bhattacharyya, S., Solakyildirim, K., Zhang, Z., Chen, ML, Linhardt, RJ, kunye neTobacman, i-JK yeseli eboshwe nge-IL-8 inyuka kwiiseli ze-epithelial ze-bronchial emva kwe-arylsulfatase B ethulisa ngenxa yokulandelwa yi-chondroitin-4- isulfate. Ndingu. J. Ukuphefumla. Iseli ye-Mol. Biol. Ngo-2010; 42: 51-61. Jonga i-abstract.
85. Schulz, A., Vestweber, A. M., kunye noDressler, D. [Isenzo esichasayo sokudumba kwesixhobo se-hyaluronic acid-chondroitin sulphate kwimodeli ye-vitro bladder]. Aktuelle Urol. Ngo-2009; 40: 109-112. Jonga i-abstract.
86. UDavid-Raoudi, M., Deschrevel, B., Leclercq, S., Galera, P., Boumediene, K., no-Pujol, JP Chondroitin sulphate yonyusa imveliso ye-hyaluronan ngama-synoviocyte omntu ngolawulo olwahlukileyo lwezihlanganisi ze-hyaluronan: Indima ye-p38 kunye I-Akt. Isifo samathambo Rheum. Ngo-2009; 60: 760-770. Jonga i-abstract.
87. Matsuno, H., Nakamura, H., Katayama, K., Hayashi, S., Kano, S., Yudoh, K., noKiso, Y. Iziphumo zokulawulwa ngomlomo kwe-glucosamine-chondroitin-quercetin glucoside kwi-synovial iipropathi ezinamanzi kwizigulana ezine-osteoarthritis kunye ne-rheumatoid arthritis. Biosci. Biotechnol. Ibhayiloji. Ngo-2009; 73: 288-292. Jonga i-abstract.
88. UKahan, A., Uebelhart, D., De, uVathaire F., uDelmas, uP.D., kunye noReginster, J. Isifo samathambo Rheum. Ngo-2009; 60: 524-533. Jonga i-abstract.
89. URovetta, G. Galactosaminoglycuronoglycan sulfate (matrix) kunyango lwe-tibiofibular osteoarthritis emadolweni. Iziyobisi kwiKlinikhi yokuHamba ngo-1991; 17: 53-57. Jonga i-abstract.
90. Oliviero, U., Sorrentino, GP, De Paola, P., Tranfaglia, E., D'Alessandro, A., Carifi, S., Porfido, FA, Cerio, R., Grasso, AM, Policicchio, D., kwaye. Iziphumo zonyango kunye ne-matrix kubantu abadala abanesifo esinganyangekiyo sobuchwephesha. Iziyobisi kwiKlinikhi yokuHamba ngo-1991; 17: 45-51. Jonga i-abstract.
91. Bruyere, O., Burlet, N., Delmas, P. D., Rizzoli, R., Cooper, C., kunye noReginster, J. Y.Uvavanyo lweempawu ezisebenza kancinci kwi-osteoarthritis esebenzisa inkqubo yeGRADE. BMC.Musculoskelet.Ukuphazamiseka. Ngo-2008; 9: 165. Jonga i-abstract.
92. I-Theoharides, T. C., Kempuraj, D., Vakali, S., kunye ne-Sant, G. R. Unyango lwe-cystitis ye-interstitial interstitial / pain pain bladder syndrome ene-CystoProtek-isongezelelo sendlela somlomo. Ngaba uJ Urol 2008; 15: 4410-4414. Jonga i-abstract.
93. IHochberg, M. C., Zhan, M., kunye neLangenberg, P. Ireyithi yokwehla kobubanzi bendawo edibeneyo kwizigulana ezine-osteoarthritis yamadolo: uphononongo olucwangcisiweyo kunye nohlalutyo lweemeta lwezilingo ezilawulwa ngokungahleliwe ze-chondroitin sulfate. I-Curr.Med.I-Rees.I-Opin. Ngo-2008; 24: 3029-3035. Jonga i-abstract.
94. Sawitzke, AD, Shi, H., Finco, MF, Dunlop, DD, Bingham, CO, III, Harris, CL, Singer, NG, Bradley, JD, Silver, D., Jackson, CG, Lane, NE, Oddis, I-CV, Wolfe, F., Lisse, J., Furst, DE, Reda, DJ, Moskowitz, RW, Williams, HJ, kunye noClegg, DO Iziphumo ze-glucosamine kunye / okanye i-chondroitin sulphate ekuqhubekeni kwedolo osteoarthritis: ingxelo ukusuka kwilingo lokungenelela kwe-glucosamine / chondroitin arthritis. Isifo samathambo Rheum. Ngo-2008; 58: 3183-3191. Jonga i-abstract.
95. UNickel, JC, Egerdie, B., Downey, J., Singh, R., Skehan, A., Carr, L., kunye no-Irvine-Bird, K. Isifundo sokwenyani sobomi bokwenyani sokuvavanya ukusebenza kunye nokhuseleko I-chondroitin sulphate ye-intravesical yonyango lwe-cystitis yangaphakathi. BJU.Int. Ngo-2009; 103: 56-60. Jonga i-abstract.
96. I-Nordling, J. kunye ne-van, i-Ophoven A. Intravesical glycosaminoglycan replenionion kunye ne-chondroitin sulphate kwiifom ezingapheliyo ze-cystitis. Iziko elinamazwe amaninzi, amaziko amaninzi, ulingo lweklinikhi lokujonga. Iifayile. Ngo-2008; 58: 328-335. Jonga i-abstract.
97. I-Theocharis, D.A, Skandalis, S. S., Noulas, A. V., Papageorgakopoulou, N., Theocharis, A. D., kunye neKaramanos, N. K. Hyaluronan kunye ne-chondroitin sulfate proteoglycans kwintlangano ye-supramolecular yomzimba we-mammalian vitreous body. Qhagamshela iTishu Res. Ngo-2008; 49: 124-128. Jonga i-abstract.
98. UFosang, A. J. kunye noLittle, C. B. Ukuqonda iziyobisi: i-aggrecanases njengeethagethi zonyango lwe-osteoarthritis. Nat Clinic Yenza iRheumatol. Ngo-2008; 4: 420-427. Jonga i-abstract.
99. UPraveen, M. R., Koul, A., Vasavada, A. R., Pandita, D., Dixit, N. V., kunye noDahodwala, F. F. DisCoVisc xa kuthelekiswa nobuchule beqokobhe elithambileyo kusetyenziswa iViscoat kunye neProvisc kwi-phacoemulsification: uvavanyo lwezonyango olungenamsebenzi. J. Cataract Refract. Utyando. Ngo-2008; 34: 1145-1151. Jonga i-abstract.
100. I-Dudics, V., Kunstar, A., Kovacs, J., Lakatos, T., Geher, P., Gomor, B., Monostori, E., kunye no-Uher, F. I-Chondrogenic enokubakho yeeseli zeseli zemeschchal ezivela kwizigulana ezine-rheumatoid. isifo samathambo kunye ne-osteoarthritis: imilinganiselo kwinkqubo ye-microculture. Iiseli Tissue. Izixhobo 2009; 189: 307-316. Jonga i-abstract.
101. UPorru, D., Cervigni, M., Nasta, L., Natale, F., Lo, Voi R., Tinelli, C., Gardella, B., Anghileri, A., Spinillo, A., kunye noRovereto, B. Iziphumo ze-endovesical hyaluronic acid / chondroitin sulfate kunyango lwe-Interstitial Cystitis / Painful Bladder Syndrome. UMfu. Iklinikhi yakutshanje yovavanyo 2008; 3: 126-129. Jonga i-abstract.
102. Cervigni, M., Natale, F., Nasta, L., Padoa, A., Voi, R. L., kunye noPorru, D. Unyango oludibeneyo lwe-intravesical kunye ne-hyaluronic acid kunye ne-chondroitin yesifo se-bladder syndrome esibuhlungu / i-cystitis yangaphakathi. I-Int.Urogynecol.J.Pelvic.Umgangatho.Ukungasebenzi. Ngo-2008; 19: 943-947. Jonga i-abstract.
103. UZhang, W., Moskowitz, RW, Nuki, G., Abramson, S., Altman, RD, Arden, N., Bierma-Zeinstra, S., Brandt, KD, Croft, P., Doherty, M., Dougados. , M., Hochberg, M., Hunter, DJ, Kwoh, K., Lohmander, LS, kunye noTugwell, P. OARSI izindululo zolawulo lwe-hip kunye nedolo le-osteoarthritis, Icandelo II: I-OARSI esekwe kubungqina, isikhokelo sokuvumelana kweengcali. I-Osteoarthritis. Ngo-2008; 16: 137-162. Jonga i-abstract.
104. URainer, G., Stifter, E., Luksch, A., kunye neMenapace, R. Thelekisa umphumo weViscoat kunye neDuoVisc kuxinzelelo lwangaphakathi lwangaphakathi lwangaphakathi emva kotyando oluncinci lwe-cataract. J. Cataract Refract. Utyando. Ngo-2008; 34: 253-257. Jonga i-abstract.
105. I-Laroche, L., Arrata, M., Brasseur, G., Lagoutte, F., Le Mer, Y., Lumbroso, P., Mercante, M., Normand, F., Rigal, D., Roncin, S., kunye no-R. , kunye. [Unyango lwesifo semehlo esomileyo kunye nejel ye-lacrimal: isifundo esingenamsebenzi se-multicenter]. J Fr. UOphtalmol kunye no-O. Ngo-1991; 14: 321-326. Jonga i-abstract.
106. IConte, A., de Bernardi, M., Palmieri, L., Lualdi, P., Mautone, G., kunye noRonca, G. Isiphelo seMetabolic se-chondroitin sulphate emntwini. Iifayile. Ngo-1991; 41: 768-772. Jonga i-abstract.
107. UBana, G., Jamard, B., Verrouil, E., kunye noMazieres, B. Chondroitin sulphate kulawulo lwehip kunye nedolo le-osteoarthritis: isishwankathelo. Ugqwetha uPharmacol. Ngo-2006; 53: 507-522. Jonga i-abstract.
108. UMazieres, B., Hucher, M., Zaim, M., kunye noGarnero, P. Iziphumo ze-chondroitin sulphate kwiimpawu zedolo le-osteoarthritis: i-multicentre, i-randomized, i-blind-blind, i-placebo elawulwa yi-placebo. UAnn Rheum Dis 2007; 66: 639-645. Jonga i-abstract.
109. UBraun, uWA, uFlynn, uMG G., uAarmstrong, uW, noJacks, D. D. Iziphumo zokuncedisa i-chondroitin sulphate kwii-indices zomonakalo wemisipha obangelwa kukuzilolonga kwengalo. IJ. YeeMidlalo. Fitness. 2005; 45: 553-560. Jonga i-abstract.
110. UMichel, BA, Stucki, G., Frey, D., De, Vathaire F., Vignon, E., Bruehlmann, P., kunye no-Uebelhart, D. Chondroitins 4 no-6 sulfate kwi-osteoarthritis emadolweni: ityala. Isifo samathambo Rheum. Ngo-2005; 52: 779-786. Jonga i-abstract.
111. URovetta, G., Monteforte, P., Molfetta, G., kunye neBalestra, V. Isifundo seminyaka emibini se-chondroitin sulphate kwi-erosive osteoarthritis yezandla: indlela yokuziphatha kwe-erosions, i-osteophytes, iintlungu kunye nokungasebenzi kwesandla. Iziyobisi kwiKlinikhi yokuHamba ngo-2004; 30: 11-16. Jonga i-abstract.
112. Mathieu, P. [Ukuqhubela phambili kwe-Radiological ye-femoro-tibial osteoarthritis yangaphakathi kwi-gonarthrosis. Impembelelo yeChondroitin ye-chondroitin sulfates ACS4-ACS6]. Misela iMed 9-14-2002; 31: 1386-1390. Jonga i-abstract.
113. IVolpi, N. Ukufumaneka komlomo ngomlomo we-chondroitin sulphate (iCondrosulf) kunye neendawo zayo kumavolontiya angamadoda asempilweni. I-Osteoarthritis. Ngo-2002; 10: 768-777. Jonga i-abstract.
114. URovetta, G., Monteforte, P., Molfetta, G., kunye neBalestra, V.Chondroitin sulphate kwi-arthrosis yezandla. Int Re Tissue React. Ngo-2002; 24: 29-32. Jonga i-abstract.
115. Steinhoff, G., Ittah, B., kunye noRowan, S.Ukusebenza kwe-chondroitin sulphate 0.2% kunyango lwe-cystitis yangaphakathi. Ngaba uJ Urol 2002; 9: 1454-1458. Jonga i-abstract.
116. O'Rourke, M. Ukuchonga ukusebenza kwe-glucosamine kunye ne-chondroitin ye-osteoarthritis. Umongikazi u-2001; 26: 44-52. Jonga i-abstract.
117. [Iziphumo eziluncedo zeChondrosulf 400 kwiintlungu kunye nomsebenzi weArthrosis: uhlalutyo lweemeta]. Misela iMed 2000; 29 (27 Suppl): 19-20. Jonga i-abstract.
118. [Uphononongo oluninzi lwaseYurophu malunga nokusebenza kwe-chondroitin sulfate kwi-gonarthrosis: ukujonga okutsha kwiziphumo ze-biochemical kunye ne-radiologic]. Misela iMed 2000; 29 (27 Suppl): 15-18. Jonga i-abstract.
119. Alekseeva, L. I., Benevolenskaia, L. I., Nasonov, E. L., Chichasova, N. V., kunye noKariakin, A. N. [Structum (chondroitin sulfate) -iarhente entsha yonyango lwe-osteoarthrosis]. Umkhombe. Ngo-1999; 71: 51-53. Jonga i-abstract.
120. I-Schwartz SR, iPark J.Ukufakwa kweBioCell Collagen, inoveli ebandaweyo yenkukhu yenkunkuma; ukuphucula i-microcirculation yegazi kunye nokunciphisa iimpawu zokuguga ebusweni. Ukwaluphala kwaKlinikhi. Ngo-2012; 7: 267-273. Jonga i-abstract.
121. I-Schauss AG, i-Stenehjem J, i-Park J, i-Endres JR, i-Clewell A. Iziphumo zenoveli ezinobunzima be-molecular hydrolyzed chicken sternal cartilage extract, i-BioCell Collagen, ekuphuculeni iimpawu ezinxulumene ne-osteoarthritis: ilingo elilawulwa ngokungahleliwe, elingaboniyo, elilawulwa yi-placebo. J Agric Ukutya Chem. Ngo-2012; 60: 4096-4101. Jonga i-abstract.
122. UKalman DS, uSchwartz HI, uPachon J, uSheldon E, uAlmada AL. Uvavanyo olungenamsebenzi olulinganisiweyo lokuvavanywa konyango lokuvavanya ukhuseleko kunye nokusebenza kohlobo lwe-hydrolyzed collagen II kubantu abadala abane-osteoarthritis. I-FASEB Biology yovavanyo lwe-2004 Abstracts, Washington DC, Epreli 17-21, 2004; A90.
123. Iivesi J, Montell E, Herrero M, et al. Uphuculo lweklinikhi kunye ne-histopathological kwi-psoriasis ngomlomo we-chondroitin sulphate: ukufumana okuqinisekileyo. I-Dermatol ekwi-Intanethi J 2005; 11: 31. Jonga i-abstract.
124. UBurke S, uShukela J, uFarber MD. Thelekisa iimpembelelo zeearhente ezimbini ze-viscoelastic, iHealon kunye neViscoat koxinzelelo lwangaphakathi lwangaphakathi lwangaphakathi emva kokungena keratoplasty. Ugqirha lwamehlo Ophthalmic 1990; 21: 821-6. Jonga i-abstract.
125. UZhang YX, uDong W, uLiu H, et al. Iziphumo ze-chondroitin sulfate kunye ne-glucosamine kwizigulana zabantu abadala abanesifo seKashin-Beck. Iiklinikhi zeRheumatol 2010; 29: 357-62. Jonga i-abstract.
126. IGauruder-Burmester A, uPopken G.Ukulandelelana kwiinyanga ezingama-24 emva konyango lwesinyi esisebenzayo kunye ne-0.2% yesodium chondroitin sulfate. Aktuelle Urol 2009; 40: 355-9. Jonga i-abstract.
127. Uebelhart D, Knussel O, Theiler R. Ukusebenza kunye nokunyamezelwa komlomo we-avian chondroitin sulphate kwi-knee osteoarthritis ebuhlungu. USchweiz Med Wochenschr 1999; 129: 1174.
128. I-Leeb BF, uPetera P, uNeumann K. Iziphumo zesifundo se-multicenter kwi-chondroitin sulfate (Condrosulf) yokusetyenziswa kwe-arthrosis yomnwe, idolo kunye ne-hip joint. IWien Med Wochenschr 1996; 146: 609-14. Jonga i-abstract.
129. UGabay C, uMedinger-Sadowski C, uGascon D, et al. Impembelelo yempawu ye-chondroitin 4 kunye ne-chondroitin 6 sulphate kwisandla se-osteoarthritis: uvavanyo lweklinikhi olulawulwa ngokungahleliwe, oluyimfama, olulawulwa yi-placebo kwiziko elinye. Isifo samathambo Rheum 2011; 63: 3383-91. Jonga i-abstract.
130. I-Yue QY, iStrandell J, i-Myrberg O. Ukusetyenziswa ngokuhambelana kweglucosamine kunokuba nefuthe le-warfarin. IZiko lokuJonga i-Uppsala. Ifumaneka apha: www.who-umc.org/graphics/9722.pdf (Ifumaneka nge-28 Epreli 2008).
131. UKnudsen J, uSokol GH. Intsingiselo yokunxibelelana kwe-glucosamine-warfarin ekhokelela kukonyuka komgangatho oqhelekileyo kwilizwe jikelele: Ingxelo yamatyala kunye nokuphononongwa koncwadi kunye nedathabheyisi yeMedWatch. I-Pharmacotherapy 2008; 28: 540-8. Jonga i-abstract.
132. UReichenbach S, uSterchi R, uSherer M, et al. Uhlalutyo lweemeta: i-chondroitin ye-osteoarthritis yedolo okanye inyonga. UAnn Intern Med 2007; 146: 580-90. Jonga i-abstract.
133. UMessier SP, uMihalko S, uLoeser RF, et al. I-Glucosamine / chondroitin edityaniswe nokuzivocavoca kunyango lwe-osteoarthritis: isifundo sokuqala. I-Osteoarthritis Cartilage 2007; 15: 1256-66. Jonga i-abstract.
134. UKahan A. STOPP (STUDY on Osteoarthritis Progression Prevention): ityala elitsha leminyaka emibini nge-chondroitin 4 & 6 sulfate (CS). Ifumaneka kwi: www.ibsa-ch.com/eular_2006_amsterdam_vignon-2.pdf (Ifumaneka nge-25 Epreli 2007).
135. UHuang J, uOlivenstein R, uThaha R, et al. Ukuphuculwa kokufakwa kweproteoglycan kwindonga yomoya yeatopic asthmatics. NdinguJ J wokuKhathalela uCrit Crit Med ngo-1999; 160: 725-9. Jonga i-abstract.
136. UClegg DO, uReda DJ, uHarris CL, et al. I-Glucosamine, i-chondroitin sulphate, kwaye zombini zidityanisiwe zedolo osteoarthritis. N Engl J Med 2006; 354: 795-808. Jonga i-abstract.
137. Uebelhart D, Malaise M, Marcolongo R, et al. Unyango olungapheliyo lwedolo le-osteoarthritis nge-chondroitin sulfate yomlomo: Unyaka omnye, i-randomize, i-blind-blind, i-multicenter Study ngokuchasene ne-placebo. I-Osteoarthritis Cartilage 2004; 12: 269-76. Jonga i-abstract.
138. USakko AJ, uRicciardelli C, uMayne K, et al. Ukumodareyitha kokuncamathiselwa kweseli yomhlaza wedlala lesibeleko kwi-matrix ngokwe-versican. Umhlaza Res 2003; 63: 4786-91. Jonga i-abstract.
139. Rozenfeld V, iCrain JL, uCallahan AK. Ukonyusa okunokwenzeka kwimpembelelo ye-warfarin yi-glucosamine-chondroitin. NdinguJ J Health Syst Pharm 2004; 61: 306-307. Jonga i-abstract.
140. UDi Caro A, uPerola E, uBartolini B, et al. Amaqhezu ee-galactosaminoglycan sulphates ezithintela imichiza inqanda iintsholongwane ezintathu ezigubungelweyo: uhlobo lomntu lwegciwane elingu-1, uhlobo lwegciwane le-herpes simplex kunye ne-cytomegalovirus yabantu. Antivir Chem Chemother 1999; 10: 33-8 .. Jonga okungafakwanga.
141. UDanao-Camara T.Iziphumo ebezingalindelekanga zonyango kunye ne-glucosamine kunye ne-chondroitin. Isifo samathambo Rheum 2000; 43: 2853. Jonga i-abstract.
142. U-Cohen M, u-Wolfe R, u-Mai T, u-Lewis D. Uvavanyo olungahleliwe, oluyimfama, olulawulwa yi-placebo lwekhrimu ye-cream ene-glucosamine sulfate, i-chondroitin sulphate, kunye ne-camphor ye-osteoarthritis emadolweni. J Rheumatol 2003; 30: 523-8 .. Jonga i-abstract.
143. UBaici A, uHorler D, uMoser B, et al. Uhlalutyo lwee-glycosaminoglycans kwi-serum yomntu emva kolawulo lomlomo lwe-chondroitin sulfate. Rheumatol Int 1992; 12: 81-8 .. Jonga i-abstract.
144. URichy F, uBruyere O, uEtgen O, et al. Ulwakhiwo kunye nokusebenza kweempawu zeglucosamine kunye ne-chondroitin kwiedolo osteoarthritis: uhlalutyo olubanzi lweemeta. IArch Intern Med 2003; 163: 1514-22. Jonga i-abstract.
145. UHenry-Launois B.Uvavanyo lokusetyenziswa kwefuthe lezezimali leChondrosulf 400 kunyango lwangoku. Inxalenye yokuQhutywa kweNtlanganiso yeSayensi ebibanjelwe kwi-XIth EULAR Symposium: Iindlela ezintsha kwi-OA: I-Chondroitin sulfate (CS 4 & 6) ayisiyonyango nje kuphela. Geneva, ngo-1998.
146. IVerbruggen G, Goemaere S, iiVenkile ze-EM. Iinkqubo zokuvavanya ukuqhubela phambili kwamalungu adibeneyo e-osteoarthritis kunye nefuthe lokuguqula isifo iziyobisi kwi-osteoarthritis. Iiklinikhi zeRheumatol 2002; 21: 231-43. Jonga i-abstract.
147. Tallia AF, Cardone DA. Ukuqaqanjelwa sisifuba okunxulunyaniswa neglucosamine-chondroitin supplement. J IBhodi yeBhodi Fam Pract 2002; 15: 481-4 .. Jonga i-abstract.
148. URicciardelli C, uQuinn DI, uRaymond WA, et al. Amanqanaba aphakamileyo e-peritumoral chondroitin sulphate aqikelela ukuqikelela okungalunganga kwizigulana ezinyangwa yi-radical prostatectomy yomhlaza webala le-Prostate. Umhlaza Res 1999; 59: 2324-8. Jonga i-abstract.
149. UYlisastigui L, Bakri Y, Amzazi S, et al. I-glycosaminoglycans enyibilikayo ayinakho ukwenza ukuba i-RANTES isebenze kwi-anti-virus kusulelo lwe-macrophage eziphambili zohlobo lwe-virus ye-immunodeficiency type 1. I-Virology 2000; 278: 412-22. Jonga i-abstract.
150. IAdebowale AO, iCox DS, uLiang Z, et al. Uhlalutyo lwe-glucosamine kunye nomxholo we-chondroitin sulphate kwiimveliso ezithengisiweyo kunye nokuqina kweCaco-2 kwezinto ze-chondroitin sulfate. UJANA 2000; 3: 37-44.
151. ICao LC, iBoeve ER, ye-Bruijn WC, et al. I-Glycosaminoglycans kunye ne-semisynthetic sulfated polysaccharides: isishwankathelo sesicelo sabo esinokubakho kunyango lwezigulana ezine-urolithiasis. Urology 1997; 50: 173-83. Jonga i-abstract.
152. UMorrison LM. Unyango lwe-coronary arteriosclerotic heart disease kunye ne-chondroitin sulfate-A: ingxelo yokuqala. J NdinguGeriatr Soc 1968; 16: 779-85. Jonga i-abstract.
153. UMorrison LM, uBajwa GS, uAlfin-Slater RB, uErshoff BH. Ukuthintela izilonda zemithambo yegazi yi-chondroitin sulphate A kwimithambo yegazi kunye ne-aorta yeempuku ezibangelwa yi-hypervitaminosis D, ukutya okune-cholesterol. I-atherosclerosis 1972; 16: 105-18. Jonga i-abstract.
154. UMazieres B, uCombe B, uPhan Van A, et al. I-Chondroitin sulphate kwi-osteoarthritis yamadolo: umntu oza kuba yimfama, ongaboniyo kabini, ohlola indawo ye-placebo elawulwa zizifo zeklinikhi. UJ Rheumatol 2001; 28: 173-81. Jonga i-abstract.
155. I-Das A Jr, iHammad TA. Ukusebenza kwendibaniselwano ye-FCHG49 glucosamine hydrochloride, TRH122 ephantsi yemolekyuli yesodium chondroitin sulphate kunye ne-manganese ascorbate kulawulo lweedolo osteoarthritis. I-Osteoarthritis Cartilage 2000; 8: 343-50. Jonga i-abstract.
156. Ukutya kunye neBhodi yeZondlo, iZiko lezeMpilo. Ukungeniswa kwereferensi yokutya kwiVitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, kunye neZinc. IWashington, DC: ICandelo leSizwe lezeMfundo, 2002. Iyafumaneka kwi: www.nap.edu/books/0309072794/html/.
157. IPipitone VR. Chondroprotection nge chondroitin sulfate. Iziyobisi kwiKlinikhi yokuHamba ngo-1991; 17: 3-7. Jonga i-abstract.
158. I-Leffler CT, iPhilippi AF, iLeffler SG, et al. I-Glucosamine, i-chondroitin, kunye ne-manganese ascorbate yezifo ezidibeneyo zokudodobala kwedolo okanye umva ophantsi: isifundo somqhubi esilawulwa ngokungahleliwe, esingaboniyo, esilawulwa yi-placebo. IMil Med 1999; 164: 85-91. Jonga i-abstract.
159. USilvestro L, uLanzarotti E, uMarchi E, et al. I-pharmacokinetics yabantu ye-glycosaminoglycans isebenzisa izinto ezinelebhile ye-deuterium kunye nezinto ezingabhalwanga: ubungqina bokutsalwa ngomlomo. Isemina iTromb Hemost 1994; 20: 281-92. Jonga i-abstract.
160. IConte A, iVolpi N, iPalmieri L, et al. Imichiza ye-Biochemical kunye ne-pharmacokinetic yonyango lomlomo kunye ne-chondroitin sulfate. IArzneimittelforschung 1995; 45: 918-25. Jonga i-abstract.
161. URonca F, uPalmieri L, uPanicucci P, et al. Umsebenzi ochasene nokuvuvukala we-chondroitin sulfate. I-Osteoarthritis Cartilage 1998; I-6 Suppl A: 14-21. Jonga i-abstract.
162. UAndermann G, uDietz M.Impembelelo yendlela yolawulo kwi-bioavailability ye-endo native macromolecule: chondroitin sulphate (CSA). I-Eur J yeziyobisi iMetab Pharmacokinet 1982; 7: 11-6. Jonga i-abstract.
163. UConte A, de Bernardi M, Palmieri L, et al. Isiphelo seMetabolic ye-chondroitin sulphate emntwini. Arzneimittelforschung 1991; 41: 768-72. Jonga i-abstract.
164. UMcAlindon TE, iLungu lePalamente yeLaValley, iGulin JP, uFelson DT. I-Glucosamine kunye ne-chondroitin kunyango lwe-osteoarthritis: uvavanyo lomgangatho olucwangcisiweyo kunye nohlalutyo lwe-meta. IJAMA 2000; 283: 1469-75. Jonga i-abstract.
165. I-Limberg MB, iMcCaa C, uKissling GE, uKaufman HE. Ukusetyenziswa kwezihloko ze-hyaluronic acid kunye ne-chondroitin sulfate kunyango lwamehlo owomileyo. NdinguJ Ophthalmol 1987; 103: 194-7. Jonga i-abstract.
166. UKelly GS. Indima yeglucosamine sulphate kunye ne-chondroitin sulphate kunyango lwezifo ezidodobalayo. Enye iMed Rev 1998; 3: 27-39. Jonga i-abstract.
167. I-Bucsi L, i-Poor G. Ukusebenza kunye nokunyamezelwa kwe-chondroitin sulphate yomlomo njengesiyobisi esisebenza kancinci kwi-osteoarthritis (SYSADOA) kunyango lwe-osteoarthritis. I-Osteoarthritis Cartilage 1998; I-6 Suppl A: 31-6. Jonga i-abstract.
168. UBourgeois P, uChales G, uDehais J, et al. Ukusebenza kunye nokunyamezeleka kwe-chondroitin sulfate 1200 mg / ngosuku vs chondroitin sulphate 3 x 400 mg / ngosuku vs placebo. Osteoarthritis Cartilage 1998; 6: 25-30. Jonga i-abstract.
169. Uebelhart D, Thonar EJ, Delmas PD, okqhubekayo. Iziphumo ze-chondroitin sulphate yomlomo ekuqhubekeni kweedolo osteoarthritis: isifundo somqhubi. Osteoarthritis Cartilage 1998; 6: 39-46. Jonga i-abstract.
170. UMorrison LM, u-Enrick N. Isifo sentliziyo seCoronary: ukunciphisa inqanaba lokufa yi-chondroitin sulphate A.I-Angiology 1973; 24: 269-87. Jonga i-abstract.
171. U-Lewis CJ. Ileta yokuphinda inkxalabo ethile yezempilo nokhuseleko yoluntu kwiifemu ezenza okanye zokungenisa elizweni izongezo zokutya eziqulathe izicubu ezithile zeenkomo.I-FDA. Ifumaneka kwi: www.cfsan.fda.gov/~dms/dspltr05.html.
172. I-Leeb BF, iSchweitzer H, iMontag K, iSmolen JS. Uhlalutyo lwe-meta lwe-chondroitin sulphate kunyango lwe-osteoarthritis. J Rheumatol 2000; 27: 205-11. Jonga i-abstract.
173. I-Bagasra O, i-Whittle P, i-Heins B, iPomerantz RJ. Uhlobo lwe-virus ye-anti-human immunodeficiency yohlobo lwe-1 lomsebenzi we-monosaccharides enesulfate: ukuthelekisa kunye ne-polysaccharides enesulfate kunye nezinye iipoliyoni. J Ukuchaphazela iDis 1991; 164: 1082-90. Jonga i-abstract.
174. UJurkiewicz E, uPanse P, uJentsch KD, et al. In vitro anti-HIV-1 umsebenzi we-chondroitin polysulphate. Isifo sikagawulayo ngo-1989; 3: 423-7. Jonga i-abstract.
175. UChavez ML. I-Glucosamine sulfate kunye ne-chondroitin sulfates. Hosp Pharm 1997; 32: 1275-85.
176. UMazieres B, uLoyau G, uMenkes CJ, et al. [Chondroitin sulphate kunyango lwe gonarthrosis kunye necoxarthrosis. Iziphumo zeenyanga ezi-5 zesifundo esilawulwa kabini esingaboniyo sisebenzisa i-placebo]. UMfu Rhum Mal Osteoartic 1992; 59: 466-72. Jonga i-abstract.
177. I-Conrozier T. [Unyango lwe-anti-arthrosis: ukusebenza kakuhle kunye nokunyamezelana kwe-chondroitin sulfates]. Misela iMed 1998; 27: 1862-5. Jonga i-abstract.
178. UMorreale P, uManopulo R, uGalati M, et al. Thelekisa ukusebenza kwe-chondroitin sulfate kunye ne-diclofenac sodium kwizigulana ezinedolo le-osteoarthritis. UJ Rheumatol 1996; 23: 1385-91. Jonga i-abstract.

Ukuhlaziywa kokugqibela-02/20/2020